Castle Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Castle Biosciences
CSTL Stock  USD 39.21  0.68  1.70%   
Castle Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Castle Biosciences' valuation are provided below:
Gross Profit
274.6 M
Profit Margin
(0.04)
Market Capitalization
1.2 B
Enterprise Value Revenue
2.6604
Revenue
343.5 M
There are over one hundred nineteen available fundamental signals for Castle Biosciences, which can be analyzed over time and compared to other ratios. We recommend to validate Castle Biosciences' prevailing fundamental drivers against the all of the trends between 2010 and 2026.

Castle Biosciences Total Revenue

400.97 Million

Check Castle Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Castle Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 4 M, Net Interest Income of 14.9 M or Interest Income of 15.6 M, as well as many indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 1.53. Castle financial statements analysis is a perfect complement when working with Castle Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Castle Stock
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Castle Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets341.8 M610.9 M206.3 M
Slightly volatile
Short and Long Term Debt Total15 M23.7 M18.2 M
Very volatile
Other Current Liabilities47.7 M45.4 M15.8 M
Slightly volatile
Total Current Liabilities59.6 M56.8 M21.1 M
Slightly volatile
Other Liabilities467.6 K492.2 K2.1 M
Very volatile
Property Plant And Equipment Net75.7 M72.1 M18.5 M
Slightly volatile
Current Deferred Revenue8 M7.6 M3.6 M
Slightly volatile
Accounts Payable4.3 M7.9 M3 M
Slightly volatile
Cash163 M137.7 M87.9 M
Slightly volatile
Non Current Assets Total206.6 M196.7 M61.1 M
Slightly volatile
Non Currrent Assets Other2.5 M2.5 M2 M
Slightly volatile
Other Assets2.4 M2.5 M2 M
Slightly volatile
Long Term Debt14.2 M8.8 M15.1 M
Slightly volatile
Cash And Short Term Investments225.3 M337.1 M130 M
Slightly volatile
Net Receivables61.8 M58.9 M19.3 M
Slightly volatile
Common Stock Total Equity30.2 K28.8 K12.8 K
Slightly volatile
Common Stock Shares Outstanding21.3 M33.6 M16.4 M
Slightly volatile
Long Term Debt Total22.5 M22.2 M19.2 M
Slightly volatile
Liabilities And Stockholders Equity341.8 M610.9 M206.3 M
Slightly volatile
Non Current Liabilities Total14.5 M23.4 M18.5 M
Very volatile
Capital Surpluse165.8 M157.9 M67.9 M
Slightly volatile
Inventory9.8 M9.4 M2.8 M
Slightly volatile
Other Current Assets4.5 M8.8 M2.9 M
Slightly volatile
Total Liabilities48.3 M86.7 M38.5 M
Slightly volatile
Property Plant And Equipment Gross91.2 M86.9 M21.5 M
Slightly volatile
Total Current Assets257.5 M414.2 M152.4 M
Slightly volatile
Net Working Capital229.2 M357.4 M133.1 M
Slightly volatile
Intangible Assets74.6 M109.9 M45.3 M
Slightly volatile
Common Stock21 K32.2 K12.9 K
Slightly volatile
Property Plant Equipment32 M30.5 M10.7 M
Slightly volatile
Capital Stock23.9 K25.2 K24.6 M
Slightly volatile

Castle Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income15.6 M14.9 M3.4 M
Slightly volatile
Depreciation And Amortization19.3 M18.4 M4.9 M
Slightly volatile
Interest Expense493.3 K519.3 K1.4 M
Slightly volatile
Selling General Administrative54.4 M88.1 M38 M
Slightly volatile
Total Revenue401 M381.9 M106.7 M
Slightly volatile
Gross Profit328.3 M312.6 M85.7 M
Slightly volatile
Other Operating Expenses390.5 M371.9 M120.9 M
Slightly volatile
Research Development62.8 M59.8 M21.4 M
Slightly volatile
Cost Of Revenue72.7 M69.2 M21 M
Slightly volatile
Total Operating Expenses317.8 M302.7 M99.9 M
Slightly volatile
Reconciled Depreciation19.3 M18.4 M4.9 M
Slightly volatile
Selling And Marketing Expenses118.7 M142 M95.5 M
Slightly volatile

Castle Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation60.8 M57.9 M17 M
Slightly volatile
Begin Period Cash Flow147.2 M113.7 M80.4 M
Slightly volatile
Depreciation19.3 M18.4 M4.9 M
Slightly volatile
Capital Expenditures34.2 M32.6 M7.5 M
Slightly volatile
End Period Cash Flow163 M137.7 M87.9 M
Slightly volatile
Issuance Of Capital Stock180.7 M288.1 M115.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.442.5610.7975
Slightly volatile
Days Sales Outstanding10264.74104
Slightly volatile
Average Payables1 M1.2 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.10.140.0796
Slightly volatile
Capex To Depreciation2.72.042.0853
Pretty Stable
EV To Sales2.132.2410.6518
Slightly volatile
Inventory Turnover8.448.5111.2615
Slightly volatile
Days Of Inventory On Hand43.4544.3940.0246
Slightly volatile
Payables Turnover4.267.855.0377
Slightly volatile
Sales General And Administrative To Revenue0.250.270.7234
Slightly volatile
Average Inventory661.2 K953.7 K783.1 K
Slightly volatile
Research And Ddevelopement To Revenue0.260.180.2737
Slightly volatile
Capex To Revenue0.08060.07680.0457
Slightly volatile
Cash Per Share7.649.55.5519
Slightly volatile
Days Payables Outstanding81.5148.1176.5975
Slightly volatile
Intangibles To Total Assets0.130.180.0977
Slightly volatile
Current Ratio6.86.565.3119
Slightly volatile
Receivables Turnover3.685.843.9417
Slightly volatile
Graham Number10.9114.0212.9358
Slightly volatile
Capex Per Share0.960.920.2679
Slightly volatile
Average Receivables6.7 M7.5 M8.2 M
Slightly volatile
Revenue Per Share11.310.764.3503
Slightly volatile
Interest Debt Per Share1.451.111.6244
Slightly volatile
Debt To Assets0.05420.0570.9834
Slightly volatile
Operating Cycle162121146
Pretty Stable
Days Of Payables Outstanding81.5148.1176.5975
Slightly volatile
Ebt Per Ebit2.352.241.3461
Slightly volatile
Long Term Debt To Capitalization0.02290.02412.6062
Slightly volatile
Total Debt To Capitalization0.05970.06282.1512
Slightly volatile
Quick Ratio6.716.415.2209
Slightly volatile
Net Income Per E B T1.050.970.978
Slightly volatile
Cash Ratio2.072.183.1774
Slightly volatile
Cash Conversion Cycle80.5373.3569.5405
Very volatile
Days Of Inventory Outstanding43.4544.3940.0246
Slightly volatile
Days Of Sales Outstanding10264.74104
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.980.511.0896
Very volatile
Fixed Asset Turnover11.026.099.5732
Pretty Stable
Debt Ratio0.05420.0570.9834
Slightly volatile
Price Sales Ratio2.442.5610.7975
Slightly volatile
Asset Turnover0.640.720.928
Slightly volatile
Gross Profit Margin0.630.740.7171
Slightly volatile

Castle Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap182.3 M205.1 M223.9 M
Slightly volatile
Enterprise Value198.4 M223.1 M243.6 M
Slightly volatile

Castle Fundamental Market Drivers

Castle Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Castle Biosciences Financial Statements

Castle Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Castle Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.6 M8 M
Total Revenue381.9 M401 M
Cost Of Revenue69.2 M72.7 M
Stock Based Compensation To Revenue 0.14  0.10 
Sales General And Administrative To Revenue 0.27  0.25 
Research And Ddevelopement To Revenue 0.18  0.26 
Capex To Revenue 0.08  0.08 
Revenue Per Share 10.76  11.30 
Ebit Per Revenue 0.02  0.02 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
How To Invest In Castle
Details
Is Castle Stock a good investment?
Details
What is Castle Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.52)
Earnings Share
(0.44)
Revenue Per Share
11.977
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.02)
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY